Merck, Lundbeck end gaboxadol development

Merck and partner H. Lundbeck have discontinued their development program for gaboxadol, an insomnia treatment currently in Phase III testing. The drugmakers cited poor results from a recent Phase III study as their reason for walking away from the program. The companies had originally planned to file an NDA in mid-2007. "The termination of our joint insomnia development program with Lundbeck is clearly disappointing," said Dr. Peter S. Kim, president of Merck Research Laboratories. "Although Merck will not be continuing with the clinical development program for gaboxadol for the treatment of insomnia, we remain committed to our neuroscience and sleep disorders research program, one of nine priority disease areas for research and product development."

- see the press release for details

ALSO: Merck has won the latest round in the Vioxx battle. Article (WSJ sub req.)

Related Articles:
New timeline for gaboxadol. Report
New sleep drug scores high in Phase II trial. Report
Teva, H. Lundbeck stop work on oral Copaxone. Report

Suggested Articles

Bristol Myers Squibb may have bounced Jounce from its roster of inherited partners, but it’s hanging onto Anokion, a Swiss autoimmune-focused biotech.

The priority review action date sets Bristol Myers up to win approval for the bluebird-partnered anti-BCMA CAR-T therapy in late March.

The unidentified biotechs are drawn from the portfolio of a €150 million life science-focused fund that Index Ventures set up.